Institutional investors purchased a net $8.6 million shares of TXMD during the quarter ended September 2017. This may signal that the smart money is gaining interest in this company as the 74.60% of the shares outstanding that institutional investors hold is among the lowest in the Pharmaceuticals: Generic industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Sold 562.3 Thousand shares of TherapeuticsMD Inc